Supplementary Figure S9 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer | Synapse
September 16, 2024
Supplementary Figure S9 from Early on-treatment changes in circulating tumor DNA fraction and response to enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
Key Points
Key points are not available for this paper at this time.
Abstract
Changes in PSA levels between baseline and 4 weeks on-treatment in the different ctDNA kinetics groups